Lilly's $300M Bet on a Biotech That Doesn't Even Have a Drug in Humans Yet
Eli Lilly just paid up to $300 million for a three-year-old startup that hasn't tested a single drug in humans. CrossBridge Bio's dual-payload ADC technology is so hot that Lilly couldn't wait for clinical data, and the deal reveals just how frenzied the ADC arms race has become.
A Three-Year-Old Startup Just Got a Nine-Figure Exit
CrossBridge Bio was founded in 2023. It has zero drugs in clinical trials. Its lead compound hasn't even been filed with the FDA yet. And Eli Lilly just agreed to buy it for up to $300 million in cash.
That's not a typo. Lilly is paying hundreds of millions of dollars for a Houston-based startup with preclinical assets and a small team. The deal, announced on April 14, tells you everything you need to know about how desperate Big Pharma has become for the next generation of cancer-killing technology.
The technology in question: dual-payload antibody-drug conjugates, or ADCs. And if you don't know what those are, buckle up, because they're the hottest category in oncology right now.
ADCs, Explained Like You're at a Dinner Party
Think of a regular ADC as a guided missile. You take an antibody (the GPS system that finds cancer cells), attach a toxic payload (the warhead), and connect them with a chemical linker (the missile body). The antibody locks onto a protein on the surface of a tumor cell, gets pulled inside, and releases its poison. Cancer cell dies. Healthy cells are mostly spared.
This concept has already produced blockbuster drugs. Six ADCs crossed $1 billion in sales in 2025, and the overall market hit roughly $13.5 billion last year. AstraZeneca's Enhertu alone raked in $3.75 billion in 2024.
But single-payload ADCs have a problem. Cancer is sneaky. Tumors develop resistance to one type of poison the same way bacteria evolve past antibiotics. Hit them with one mechanism, and eventually they figure out a workaround.
The fix? Strap two different warheads onto the same missile.
That's what CrossBridge Bio does. Their dual-payload ADCs deliver two distinct cancer-killing drugs simultaneously, attacking tumors through different pathways at once. It's like fighting a chess match on two boards: even if the tumor finds a defense against one attack, the second one is already landing.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
CrossBridge Bio was co-founded by Dr. Kyoji Tsuchikama at the University of Texas Health Science Center at Houston, with Michael Torres serving as CEO. The company's platform uses a clever combination of microbial transglutaminase and click chemistry (two lab techniques for precisely attaching molecules) to build these dual-payload ADCs with unusual precision.
Why does precision matter? Because the ratio of drug to antibody determines whether your medicine works or poisons the patient. CrossBridge's technology lets scientists control exactly how many molecules of each payload get attached, producing a clean, consistent product. Traditional approaches to dual-payload ADCs have been messy, with lots of waste and unpredictable results. CrossBridge's modular system is essentially a Lego set for building cancer drugs.
Their lead candidate, CBB-120, targets a protein called TROP2 (a popular ADC target already used by drugs like Trodelvy). But CBB-120 packs two punches: a topoisomerase 1 inhibitor and an ATR inhibitor, each attacking cancer DNA through different mechanisms. In preclinical studies, it showed tumor regressions and even complete responses in animal models of solid tumors, including tumors that had already become resistant to existing TROP2 ADCs.
An IND filing (the application that lets you start testing in humans) is expected sometime in 2026. CrossBridge had previously raised a $10 million seed round led by TMC Venture Fund and CE-Ventures, plus a $15 million grant from the Cancer Prevention and Research Institute of Texas. Going from $25 million in total funding to a $300 million acquisition in roughly three years is an extraordinary return.
Lilly's Shopping Spree Is Getting Hard to Track
CrossBridge isn't a one-off. Lilly has been on an absolute tear in 2026, buying biotechs like a kid with birthday money at a candy store.
In April alone, the company scooped up Kelonia Therapeutics for up to $7 billion ($3.25 billion upfront) to get in vivo CAR-T cell therapy. Before that, it grabbed Orna Therapeutics for up to $2.4 billion, also in the CAR-T space. There's a $1.12 billion gene-editing partnership with Seamless Therapeutics. A $1 billion acquisition of Verve Therapeutics. A $1.2 billion deal for Ventyx in inflammation. Adverum Biotechnologies for $261 million. A $475 million deal with MeiraGTx. A hearing-loss partnership with Rznomics worth up to $1.3 billion.
The strategy is clear: Lilly made a fortune on GLP-1 drugs (think Mounjaro and Zepbound), and now it's reinvesting those profits into building a diversified pipeline before the competition catches up. Oncology is the biggest bet. The company already has sofetabart mipitecan (an ADC with breakthrough therapy designation for platinum-resistant ovarian cancer) and three other ADCs in phase 2 trials. CrossBridge adds the next-generation dual-payload twist.
On the ADC front specifically, CrossBridge joins a lineage that includes Lilly's 2023 acquisition of Mablink Bioscience and its earlier purchase of Emergence Therapeutics, a European ADC developer.
The Billion-Dollar Arms Race Behind This Deal
Lilly isn't spending this money in a vacuum. The entire pharmaceutical industry is scrambling for ADC technology, and the deals keep getting bigger.
Pfizer set the tone with its $43 billion acquisition of Seagen in late 2023, which gave it control of Adcetris ($1.91 billion in sales) and Padcev. That deal essentially fired the starting gun.
Since then, Gilead dropped $5 billion on Tubulis in April 2026 for its Tubutecan ADC platform. Boehringer Ingelheim agreed to a licensing deal with Synaffix worth up to $1.3 billion in milestone payments. Astellas signed an exclusive licensing agreement with Evopoint Biosciences worth up to $1.54 billion in potential deal value. Taiho paid $1.14 billion for Araris Biotech's linker technology. AbbVie invested $10.1 billion in ImmunoGen for its ovarian cancer ADC Elahere.
The pattern is unmistakable: companies aren't just buying individual drugs anymore. They're buying platforms, the underlying technology that can generate whole portfolios of ADCs. CrossBridge Bio's dual-payload system fits that mold perfectly.
There are now over 200 ADC candidates in clinical development worldwide. The market is projected to reach $15.4 to $20 billion in 2026. And the payload technology market alone (the warhead chemistry that makes ADCs work) is expected to grow from $469 million to $720 million by 2035.
The $300 Million Question
So is CrossBridge Bio worth $300 million? The honest answer: it depends entirely on whether the science works in humans.
Preclinical data can be deceiving. Plenty of drugs that cure cancer in mice fail spectacularly in people. CBB-120 hasn't been tested in a single patient yet. The IND filing hasn't even happened. Lilly is essentially paying for a platform, a team, and a hypothesis.
But the deal structure suggests Lilly is hedging. The $300 million is split into an undisclosed upfront payment and a milestone payment tied to a future development goal. If CrossBridge's tech doesn't hit certain marks, Lilly won't pay the full amount. That's a classic biotech deal structure: share the risk, cap the downside.
The real value isn't CBB-120 alone. It's what CrossBridge's modular dual-payload system could produce across dozens of future ADC programs. If you can swap different antibodies and different payload combinations in and out like interchangeable parts, you don't just have one drug candidate; you have a factory for making them.
The Pfizer Shadow
There's one nagging concern with Lilly's buying binge. At least one industry observer has raised the question of whether Lilly can "avoid Pfizer's fate."
Pfizer's post-COVID acquisition spree (Seagen, Arena, Global Blood Therapeutics, Biohaven) totaled over $60 billion and left the company struggling to integrate everything while its stock price cratered. Serial dealmaking sounds great in a press release. Integration is where empires stumble.
Lilly has advantages Pfizer didn't: a cash-printing GLP-1 franchise, a more focused therapeutic strategy, and (so far) smaller individual deal sizes outside of Kelonia. But the pace of acquisitions since 2023 is a lot of moving pieces. At some point, the question shifts from "Can you find good targets?" to "Can you actually run all of this?"
The Bottom Line
Lilly's CrossBridge buy is a relatively small bet by the company's recent standards. Three hundred million is a rounding error next to $7 billion for Kelonia or $2.4 billion for Orna. But it's a smart one.
Dual-payload ADCs represent the next logical step in a drug class that's already generating billions. CrossBridge's platform solves a real manufacturing problem (making dual-payload ADCs consistently and cleanly) that has held back the field. And the deal structure protects Lilly if things go sideways in the clinic.
The bigger story is what this says about the ADC market in 2026. When a preclinical startup with $25 million in total funding gets a $300 million buyout three years after founding, that's not just one company getting lucky. That's an industry telling you exactly where it thinks the future is headed. And right now, that future looks like two warheads are better than one.
Science & Discovery
4 min read
The Gene Therapy That's Making Deaf People Hear Whispers
A gene therapy trial just restored hearing in 90% of deaf patients, some within weeks of a single injection. The results are 'mind-boggling,' and pharma companies are spending billions to win the race.
